Yingyingloo
2021-09-01
Good
AC Immune shares surged more than 70% in early trading
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":816005812,"tweetId":"816005812","gmtCreate":1630453711736,"gmtModify":1631892127167,"author":{"id":4090502512947490,"idStr":"4090502512947490","authorId":4090502512947490,"authorIdStr":"4090502512947490","name":"Yingyingloo","avatar":"https://static.tigerbbs.com/da58afbd656809ec183af4a539b38af6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good</p></body></html>","htmlText":"<html><head></head><body><p>Good</p></body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/816005812","repostId":1174676883,"repostType":4,"repost":{"id":"1174676883","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1630417268,"share":"https://www.laohu8.com/m/news/1174676883?lang=&edition=full","pubTime":"2021-08-31 21:41","market":"us","language":"en","title":"AC Immune shares surged more than 70% in early trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174676883","media":"Tiger Newspress","summary":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner","content":"<p>AC Immune shares surged more than 70% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b> and its collaborating partner <b>Genentech</b>, part of <b>Roche Holdings AG</b>, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune shares surged more than 70% in early trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune shares surged more than 70% in early trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-31 21:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AC Immune shares surged more than 70% in early trading.</p>\n<p><img src=\"https://static.tigerbbs.com/9e1ae2e20dee3043b692297f3834cf6d\" tg-width=\"878\" tg-height=\"616\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li><b>AC Immune SA</b> and its collaborating partner <b>Genentech</b>, part of <b>Roche Holdings AG</b>, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).</li>\n <li>Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.</li>\n <li>Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.</li>\n <li>Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.</li>\n <li>There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.</li>\n <li>Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.</li>\n <li>Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174676883","content_text":"AC Immune shares surged more than 70% in early trading.\n\n\nAC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.","news_type":1},"isVote":1,"tweetType":1,"viewCount":149,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/816005812"}
精彩评论